Extraprostatic lesions: in the first 11 patients who got only IAB2M, 3 patients had 7 extra-prostatic lesions; 4 extra-prostatic lesions were detected and confirmed by surgical path and 3 lesions were missed. In the subsequent 9 patients who got both PET scans, 4 extraprostatic lesions in one patient were detected by both PET agents, 3 were confirmed by surgical pathology and 1 confirmed on bone scan 2 months post-op. 15 false positive lesions were detected by IAB2M in 20 patients and 5 false positives were detected by PSMA-11 in the last 9 patients. There were 11 false negative lesions on IAB2M in all 19 patients and 3 false negatives on PSMA-11 in 8 patients. Of these false negatives, 7 were GS 6 and 2 were 3þ4 and LNs median size was 2mm (0.5-15).
INTRODUCTION AND OBJECTIVES:
Conventional imaging has a limited yield for the detection of recurrent disease at low PSA levels. The use of PET/CT with a range of radiotracers has shown early promise in improving cancer detection in this setting. Therefore, we assess the relationship between PSA levels and 18F-Fluciclovine PET/ CT positivity in patients with biochemical recurrence.
METHODS: A consecutive sample of men who underwent 18F-Fluciclovine PET/CT for biochemical recurrence at a single institution were included in this retrospective study. Patients were stratified into groups according to their serum PSA level (A: <0.5 ng/mL, B: 0.5-1.0 ng/mL, C: 1-1.5 ng/mL, D: 1.5-2.0 ng/mL, E: >2.0ng/mL) and the rate of scan positivity were compared between groups. Multivariable logistic regression analysis adjusting for patient, tumor and treatment charcteristics was performed to characterise the affect of PSA on yield. We also compared the SUVmax, SUVtotal and MTV between the groups.
RESULTS: A total of 76 patients with complete PSA data were included with 63.2% (n[48) having a positive 18F-Fluciclovine PET/ CT. The positivity rate for each of the groups were A: 0%, B: 66.7%, C: 70%, D: 72.7%, E: 78.4% (p<0.01). PSA acted as a significant predictor of positivity (OR 2.04 per unit increase, 95%CI 1.23-4.79). There was also a significant difference in SUVmax between the groups which increased with PSA levels (p[0.009). There was no difference in SUVtotal or MTV between the groups.
CONCLUSIONS: The yield of 18F-Fluciclovine PET/CT in patients with a PSA <0.5 ng/mL is low and therefore this scan should only be performed in patients with a PSA above this level.
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⁶⁸GA-PSMA PET-CT AND MULTI-FREQUENCY-BAND RASTER-SCAN OPTOACOUSTIC MESOSCOPY AS IMAGING METHODS FOR RELAPSE DETECTION AND SUCCESS PREDICTION OF VASCULAR TARGETED PHOTODYNAMIC THERAPY IN A PROSTATE CANCER MODEL
Ricardo Alvim*, Katja Haedicke, Karan Nagar, Sudeep Das, Alexander Somma, New York, NY; Christopher Hughes, New york, NY; Avigdor Scherz, Rehovot, Israel; Kwanghee Kim, Jan Grimm, Jonathan Coleman, New York, NY INTRODUCTION AND OBJECTIVES: Limitations of standard assessments (MRI and PSA) used to follow patients with prostate cancer who receive focal therapy suggest that novel imaging approaches are needed. In this study, we assessed whether Gallium-68 PSMA PET-CT and multi-frequency-band raster-scan optoacoustic mesoscopy (RSOM) can be used to detect and predict relapse after vascular targeted photodynamic therapy (VTP) METHODS: 1Â106 LNCaP-AR cells were grafted in the flanks of 6-8 week old SCID mice (n[24). VTP (150 mW/cm2) was performed six weeks after implantation to ablate the tumor cells (n[20) . Control mice (n[4) did not receive VTP ablation. Blood PSA level assessment,
68
Ga-PSMA PET-CT, and RSOM images were performed 2 days before VTP and 1 and 3 weeks after. Mice were euthanized 4 weeks post-VTP and tumors were assessed by histology.
RESULTS: Of the 17 VTP-treated mice alive 4 weeks after ablation, 11 (65%) had completely ablated tumors and 6 (35%) had tumor relapse confirmed by histology. One week after VTP, mice that relapsed had an elevated PSMA PET-CT signal compared to very low in completely ablated tumors (p<0.01, Figure 1 ). Heat-Map Histogram analysis of pre-VTP RSOM data showed more intense signal in the ablation group than the relapse group (p[0.04) and lower vessels density in relapsed tumors (vessels/Tu area; p[0.03, Figure 2 ). PSA level was not useful for detecting relapse one week
